Elstein Amir 4

What Happened
Amir Elstein, a director of Teva Pharmaceutical Industries Ltd. (TEVA), received a grant of 7,242 restricted share units (RSUs) on May 28, 2026. The RSUs were granted at $0.00 (a compensation award rather than a purchase); the filing treats this as a derivative award that may convert to ordinary shares or cash on settlement.

Key Details

• Transaction date: 2026-05-28; transaction type: A (award/grant).
• Shares/units granted: 7,242 RSUs; reported acquisition price: $0.00.
• Vesting: RSUs vest on 2027-05-28 (one-year vesting period) (Footnote F2).
• Derivative terms: Each RSU represents a contingent right to one ordinary share or, at the committee’s option, the cash value of one ordinary share (Footnote F1).
• ADS note: Ordinary shares may be represented by American Depositary Shares (1 ADS currently = 1 ordinary share) (Footnote F3).
• Shares owned after transaction: not specified in the provided filing.
• Filing timeliness: Form 4 was filed on 2026-06-01 for the 2026-05-28 grant; this meets the SEC’s two-business-day reporting requirement.

Context
RSU grants are a form of compensation and do not represent an open-market purchase or sale; they typically indicate retention or compensation rather than a direct market sentiment signal. The awarded units convert to shares (or cash) only after vesting and any settlement, so they do not increase tradable share count until vested and settled.